Dermata Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 15, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

DRMA$0.71-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

	For the three months endedMarch 31,
2024 · 2023
Cash flows from operating activities:
Net loss		$(3,134,262)		$(2,240,142)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		587,234		131,260
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets		94,424		174,848)
Accounts payable		(43,482)		(3,831)
Accrued and other current liabilities		(208,368)		288,232
Total adjustments to reconcile net loss to net cash used in operations		429,808		590,509
Net cash used in operating activities		(2,704,454)		(1,649,633)
Cash flows from financing activities:
Proceeds from issuance of Common Stock and warrants, net of issuance costs		-		4,174,985
Proceeds from exercise of pre-funded warrants		-		153
Payment for fractional shares in reverse stock split		-		(40)
Net cash provided by financing activities		-		4,175,098
Net increase (decrease) in Cash and cash equivalents		(2,704,454)		2,525,465
Cash and cash equivalents at beginning of period		7,438,135		6,241,294
Cash and cash equivalents at end of period		$4,733,681		$8,766,759
Non-cash financing activities:
Issuance of abeyance shares		$(273)	$	-
Incremental fair value of March 2023 warrant modification	$	-		$144,765

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.